Clinical  	Clinical  	 JJ	B-NP
roundtable  	roundtable  	 JJ	I-NP
monograph 	monograph 	 NN	I-NP
:  	:  	 :	O
Recent  	Recent  	 JJ	B-NP
advances  	advances  	 NNS	I-NP
in  	in  	 IN	O
taxanes  	taxanes  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
first-line  	first-line  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
Treatments  	Treatments  	 NNS	I-NP
for  	for  	 IN	I-NP
non-small  	non-small  	 JJ	I-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
NSCLC 	NSCLC 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
broad  	broad  	 JJ	O
categories  	categories  	 NNS	O
of  	of  	 IN	O
squamous  	squamous  	 NN	B-NP
or  	or  	 CC	O
non-squamous  	non-squamous  	 JJ	B-NP
histology 	histology 	 NN	I-NP
.  	.  	 .	O
Frontline  	Frontline  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
options  	options  	 NNS	I-NP
include  	include  	 VBP	O
pemetrexed  	pemetrexed  	 VBN	O
and  	and  	 CC	O
cisplatin 	cisplatin 	 NN	B-NP
,  	,  	 ,	O
pemetrexed  	pemetrexed  	 NN	O
and  	and  	 CC	O
a  	a  	 DT	O
taxane 	taxane 	 NN	B-NP
,  	,  	 ,	O
gemcitabine  	gemcitabine  	 VBG	O
with  	with  	 IN	O
cisplatin 	cisplatin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	O
bevacizumab  	bevacizumab  	 VBG	O
to  	to  	 TO	O
a  	a  	 DT	O
taxane  	taxane  	 NN	B-NP
and  	and  	 CC	O
carboplatin 	carboplatin 	 NN	B-NP
.  	.  	 .	O
Pemetrexed  	Pemetrexed  	 NNP	O
is  	is  	 VBZ	O
used  	used  	 VBN	O
for  	for  	 IN	O
maintenance  	maintenance  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	I-NP
non-squamous  	non-squamous  	 NNP	I-NP
NSCLC 	NSCLC 	 NNP	I-NP
,  	,  	 ,	O
whereas  	whereas  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
squamous  	squamous  	 JJ	B-NP
NSCLC  	NSCLC  	 NNS	I-NP
lack  	lack  	 VBP	O
easy  	easy  	 JJ	O
options  	options  	 NNS	O
for  	for  	 IN	O
maintenance  	maintenance  	 NN	B-NP
therapy.  	therapy.  	 NNP	I-NP
nab-Paclitaxel  	nab-Paclitaxel  	 NNP	O
overcomes  	overcomes  	 VBZ	O
the  	the  	 DT	O
solubility  	solubility  	 NN	B-NP
and  	and  	 CC	O
toxicity  	toxicity  	 JJ	B-NP
issues  	issues  	 NNS	I-NP
of  	of  	 IN	O
solvent-based  	solvent-based  	 JJ	O
paclitaxel 	paclitaxel 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
albumin  	albumin  	 NN	B-NP
in  	in  	 IN	O
nab-paclitaxel  	nab-paclitaxel  	 NNP	B-NP
improves  	improves  	 VBZ	O
the  	the  	 DT	O
concentration  	concentration  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
drug  	drug  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
tumor 	tumor 	 NN	B-NP
.  	.  	 .	O
A  	A  	 DT	O
recent  	recent  	 JJ	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trial  	trial  	 NN	O
in  	in  	 IN	O
NSCLC  	NSCLC  	 NNP	B-NP
compared  	compared  	 VBD	O
nab-paclitaxel  	nab-paclitaxel  	 JJ	B-NP
with  	with  	 IN	O
carboplatin  	carboplatin  	 FW	B-NP
versus  	versus  	 FW	O
solvent-based  	solvent-based  	 FW	O
paclitaxel  	paclitaxel  	 FW	B-NP
with  	with  	 IN	O
carboplatin 	carboplatin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
found  	found  	 VBD	O
improved  	improved  	 VBN	O
overall  	overall  	 JJ	B-NP
response  	response  	 NN	I-NP
rates  	rates  	 NNS	I-NP
( 	( 	 -LRB-	O
ORRs 	ORRs 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
nab-paclitaxel  	nab-paclitaxel  	 JJ	B-NP
arm  	arm  	 NN	I-NP
( 	( 	 -LRB-	O
33 	33 	 CD	O
%  	%  	 NN	O
vs  	vs  	 VBD	O
25 	25 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
P=.005 	P=.005 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
subset  	subset  	 JJ	B-NP
analysis 	analysis 	 NN	I-NP
,  	,  	 ,	O
NSCLC  	NSCLC  	 NNP	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
squamous  	squamous  	 JJ	B-NP
histology  	histology  	 NN	I-NP
had  	had  	 VBD	O
a  	a  	 DT	O
higher  	higher  	 JJR	O
ORR  	ORR  	 NNP	B-NP
( 	( 	 -LRB-	O
41 	41 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
nab-paclitaxel  	nab-paclitaxel  	 JJ	B-NP
than  	than  	 IN	O
with  	with  	 IN	O
solvent-based  	solvent-based  	 JJ	O
paclitaxel  	paclitaxel  	 NNS	B-NP
( 	( 	 -LRB-	O
24 	24 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
P  	P  	 NNP	O
< 	< 	 SYM	O
.001 	.001 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Another  	Another  	 DT	O
subset  	subset  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
found  	found  	 VBD	O
that  	that  	 IN	O
patients  	patients  	 NNS	O
ages  	ages  	 VBD	O
70  	70  	 CD	O
years  	years  	 NNS	O
and  	and  	 CC	O
older  	older  	 JJR	O
had  	had  	 VBD	O
improved  	improved  	 VBN	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
( 	( 	 -LRB-	O
median  	median  	 JJ	B-NP
19.9  	19.9  	 CD	O
months 	months 	 NNS	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
nab-paclitaxel  	nab-paclitaxel  	 JJ	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
solvent-based  	solvent-based  	 JJ	O
paclitaxel  	paclitaxel  	 NNS	B-NP
( 	( 	 -LRB-	O
median  	median  	 JJ	B-NP
10.4  	10.4  	 CD	O
months 	months 	 NNS	O
;  	;  	 :	O
P=.009 	P=.009 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
nab-paclitaxel  	nab-paclitaxel  	 JJ	B-NP
arm  	arm  	 NN	I-NP
had  	had  	 VBD	O
less  	less  	 JJR	O
neuropathy 	neuropathy 	 NN	B-NP
,  	,  	 ,	O
less  	less  	 JJR	O
hearing  	hearing  	 NN	B-NP
loss 	loss 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
fewer  	fewer  	 JJR	O
interruptions  	interruptions  	 NNS	B-NP
in  	in  	 IN	O
daily  	daily  	 JJ	O
living  	living  	 NN	O
than  	than  	 IN	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
solvent-based  	solvent-based  	 JJ	O
paclitaxel  	paclitaxel  	 JJ	B-NP
arm 	arm 	 NN	I-NP
.  	.  	 .	O
